Skip to content Skip to sidebar Skip to footer

SK Life Sciences Presents Groundbreaking Cancer Research at AACR Annual Meeting

KING OF PRUSSIA, PA — SK Life Science Labs, a division of SK Biopharmaceuticals Co., Ltd., showcased pioneering research at the annual meeting of the American Association for Cancer Research (AACR) held in Chicago in 2025. The study emphasizes the promise of new oral p300-specific proteolysis-targeting chimeras (PROTACs) as treatments for difficult-to-tackle cancers such as prostate cancer and conditions involving defects or alterations in the CBP protein.

The p300 protein plays a critical role in driving tumor growth across a range of cancers. The research unveiled by SK Life Science Labs demonstrates that these targeted degraders shut down tumor cell proliferation with precision and potency. Administered orally once daily, p300-selective degraders showed rapid tumor reduction in preclinical models, particularly in cases of castrate-resistant prostate cancer and other hard-to-treat indications.

What makes our research particularly promising is that we've demonstrated that selective p300 degraders can swiftly halt tumor growth in difficult-to-treat cancers with increased efficacy and reduced side effects thanks to their targeted approach," said Dr. Ryan Kruger, Chief Scientific Officer at SK Life Science Labs. "This study brings significant optimism for the creation of more secure medication treatments that might successfully address some of the toughest cancer cases for those lacking viable therapeutic choices.

One major benefit of the p300 degraders is their capacity to specifically focus on the p300 protein without affecting the similar CBP protein. In contrast to current therapies that only inhibit the function of proteins, these degraders completely remove p300 from the equation, which makes them an appealing choice as a treatment for cancers dependent on this particular protein.

Dr. Kruger stated, "There are two main benefits of employing a heterobifunctional degrader to target p300. Firstly, leveraging the strength of ternary complex formation allows us to create compounds that specifically target p300 over CBP with remarkable precision. Secondly, unlike other developing molecules which merely inhibit p300’s function, these degraders remove this essential protein from cancerous cells entirely. This breakthrough highlights the promise of safer and more potent treatments for certain hard-to-cure forms of cancer."

The breakthrough at SK Life Science Labs marks considerable advancement in battling aggressive forms of cancer. This achievement highlights their dedication to developing cutting-edge therapies designed to enhance medical treatment for patients.

Post a Comment for "SK Life Sciences Presents Groundbreaking Cancer Research at AACR Annual Meeting"